Metabolic + Cardiovascular
Overview
We are exploring the potential of Bicycles to target cardiovascular and metabolic diseases through our partnership with AstraZeneca.
In November 2016, Bicycle partnered with a world leader in respiratory science, AstraZeneca, to evaluate the potential for local delivery of inhaled Bicycles in the lung and showed that we could drug a number of hard-to-drug respiratory targets in an innovative way. We also showed that they were highly bioavailable following topical lung administration and that they could be stabilized to the harsh enzymatic environment of the lung.
We also showed that we could successfully drug a number of cardiovascular/metabolic disease targets. The partnership was expanded in March 2018 due to the success of the initial screening campaigns.
In addition to the significant patient benefit that may result from this collaboration, Bicycle can also receive significant milestone and royalty payments.
